All Online

1 - 4 of 4 results


Active filters


e-Cigarettes were 1st introduced to the US market in 2007, essentially to help smokers stop smoking tobacco-based cigarettes. There is some evidence that, for some adults, it may be beneficial to assist with smoking cessation. However, the use of e-Cigarettes and vaping (referred to as ENDS – electronic nicotine delivery systems), has increased significantly, specifically in the US teen population. The FDA and AAP have addressed the concerns surrounding e-Cigarettes and vaping in both regulations and policy statements. Join us as we discuss the latest evidence, potential benefits, and public health concerns regarding e-Cigarettes and vaping. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on February 7, 2020 and they are subject to change as new information is published.


Cannabis use continues to rise in the United States, driven by expansion of laws legalizing recreational and medical use. With this increased use comes an increase in side effects, such as lung injuries from vaping and a rise in cannabis use disorder. We will discuss what practitioners should know about vaping and cannabis use, and what they should tell their patients. This session will also inform the attendees the most recent clinical and radiographic findings in patients diagnosed with e-cigarette and vaping associated acute lung injury.


Vaping: Health Threats in a Rapidly Changing Landscape - Frankly Speaking EP 151

Guest: Susan Feeney, DNP, FNP-BCMusic Credit: Richard Onorato

0.25 CME

Every day new information on e-cigarettes is in the media – the explosion of teen use with a resulting epidemic of nicotine addiction and most recently, increasing cases of serious lung related illness associated with vaping. Join us as we discuss this epidemic and the emergence of VAPI (Vaping Associated Pulmonary Injury)


In the last year, two new diseases have emerged with significant and lasting impact on the lung: E-cigarette or Vaping Product Use-Associated Lung Injury (EVALI) and COVID-19 pneumonia. This session will address new information and challenges related to both diseases. Vaping has increased in popularity, especially among youth, and in late 2019, EVALI was first described. While the outbreak has subsided, recognition of the symptoms, association with marijuana use, and radiographic findings of EVALI remain important. Further, providing tobacco and marijuana cessation guidance remains critical. The COVID-19 pandemic, caused by SARS-Cov2 virus, has burdened healthcare workers and scientists across the globe. COVID-19, often associated with severe pneumonia and systemic illness, has resulted in significant morbidity and mortality in the US and we can continue to learn and discover its full impact. Additionally, COVID-19 has unmasked major health disparities in our healthcare system that we must address.